603707.SS SHH

Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of drugs and APIs in China. It also provides heparin sodium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, atracurium besylate, cisatracurium, calcium folinate, doxorubicin, milrinone, bleomycin, carboplatin, cytarabine, topotecan hydrochloride, phenylephrine hydrochloride, ganirelix acetate, furosemide, glycopyrrolate, neostigmine methylsulfate, succinylcholine chloride, reganosin, isoflurane blue, clofarabine, haloperidol decanoate, busulfan, gemcitabine hydrochloride, dexmedetomidine hydrochloride, nelarabine, rocuronium bromide, zoledronic acid, bupivacaine hydrochloride, plerixafor, eptifibatide, fondaparinux sodium, docetaxel, fluorouracil, palonosetron hydrochloride, oxaliplatin, fulvestrant, and adalimumab injections. The company offers bortezomib, bendamustine hydrochloride, mycophenolate mofetil, vancomycin hydrochloride, daptomycin, decitabine, voriconazole, tigecycline, melphalan hydrochloride, actinomycin, micafungin, azacitidine, pantoprazole sodium, mitomycin, pemetrexed disodium, thiotepa, and dacarbazine for injections. Its injection products cover anticoagulation, anti-tumor, cardiovascular disease, as well as surgical anesthesia, anti-bacterial infection, and angiography. The company was founded in 2000 and is headquartered in Nanjing, China.